In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.
Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. evanyu [at] uw.edu
Clin Nucl Med. 2011 Mar;36(3):192-8
© Galenicom 1999-2013